EPS of $-95.95 decreased by 73% from previous year
Net income of -358.58K
"N/A" - N/A
Propanc Biopharma Inc (PPCB) QQ4 2024 Results Analysis — Preclinical Biotech with Minimal Revenue, Elevated Burn, and Leverage Risk in OTC Market
Executive Summary
Propanc Biopharma Inc. (PPCB) reported QQ4 2024 with no reported revenue and a pronounced operating burn. The quarter shows a net loss of $358.6k on a per-share basis of -$95.95, driven by ongoing R&D and substantial G&A expenses, and a meaningful interest burden. Cash burn persisted, with operating cash flow negative by $259.97k and little to no cash generated from operations, while financing activities provided a modest $250.97k, yielding a net cash increase of only $14.86k for the quarter. The balance sheet reveals a fragile liquidity position: total assets of $72.4k versus total liabilities of $3.85 million and negative shareholder equity of nearly $3.78 million. Liquidity metrics are severely depressed (current ratio ~0.0067, cash ratio ~0.0056), underscoring a precarious financial runway reliant on continued external funding. The company continues to operate at the preclinical stage with PRP as the lead program and faces the standard biotech financing and regulatory risk that accompanies such an enterprise. No earnings call transcript was provided in the data, limiting the ability to extract management insights directly from an earnings call. Investors should focus on runway, liquidity improvements, potential milestone-based partnerships, and any new clinical or licensing catalysts in upcoming disclosures.
Key Performance Indicators
Operating Income
-259.90K
QoQ: 38.25% | YoY:-23.76%
Net Income
-358.58K
QoQ: 31.92% | YoY:52.06%
EPS
-95.95
QoQ: 67.67% | YoY:-73 707.69%
Revenue Trend
Margin Analysis
Key Insights
Net cash provided by operating activities: -$259,966.
Net change in cash: +$14,863; cash at end of period: $21,085; cash at beginning of period: $6,222.
Free cash flow: -$259,966 (equivalent to CFO given no capex in the period).
Total assets: $72,365; cash and cash equivalents: $21,085; total current assets: $25,441; net property, plant & equipment: $17,799; non-current assets: $46,924.
Total liabilities: $3,851,424; total current liabilities: $3,792,782; short-term debt: $889,629; long-term debt: $58,642; total debt: $948,271; net debt: $927,186.
Financial Highlights
Revenue: Not reported (null) for QQ4 2024; no QoQ or YoY revenue data available.
Gross Profit: -$5,764 for QQ4 2024; Gross Profit Margin not meaningful as revenue is null.
Operating Income: -$259,899 in QQ4 2024; YoY change -23.76%; QoQ change +38.25% (as reported in the ratios data).
Net Income: -$358,578 in QQ4 2024; YoY change +52.06%; QoQ change +31.92% (as reported).
Earnings Per Share (EPS): -$95.95 (both basic and diluted); YoY and QoQ percentages shown as -73,707.69% and +67.67% respectively in the data.
EBITDA: -$263,047 in QQ4 2024.
Cash Flow and Liquidity:
- Net cash provided by operating activities: -$259,966.
- Net change in cash: +$14,863; cash at end of period: $21,085; cash at beginning of period: $6,222.
- Free cash flow: -$259,966 (equivalent to CFO given no capex in the period).
Balance Sheet Highlights:
- Total assets: $72,365; cash and cash equivalents: $21,085; total current assets: $25,441; net property, plant & equipment: $17,799; non-current assets: $46,924.
- Total liabilities: $3,851,424; total current liabilities: $3,792,782; short-term debt: $889,629; long-term debt: $58,642; total debt: $948,271; net debt: $927,186.
- Total stockholders’ equity: -$3,779,059; accumulated deficit indicates ongoing cumulative losses.
- Liquidity ratios: current ratio 0.0067; quick ratio 0.0067; cash ratio 0.0056; cash conversion and days payables indicate an elevated working capital risk.
Notes: The figures reflect a biotech microcap in preclinical development with no reported revenue in QQ4 2024 and substantial reliance on external financing to fund ongoing burn. The reported yoy and qoq percentage changes for profitability metrics are provided in the dataset, but may be distorted by negative bases and non-operating items. The earnings transcript in the data is empty, so management commentary and forward guidance via call quotes are not available in this dataset.
Income Statement
Metric
Value
YoY Change
QoQ Change
Gross Profit
-5.76K
-3.73%
N/A
Operating Income
-259.90K
-23.76%
38.25%
Net Income
-358.58K
52.06%
31.92%
EPS
-95.95
-73 707.69%
67.67%
Key Financial Ratios
currentRatio
0.01
returnOnAssets
-496%
returnOnEquity
9.49%
debtEquityRatio
-0.25
operatingCashFlowPerShare
$-0
freeCashFlowPerShare
$-0
priceToBookRatio
-16474
priceEarningsRatio
-43405
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Earnings call transcript is not provided in the supplied data (earningsTranscript: []).
As a result, no management quotes or theme-based insights from an earnings call are extractable. The analysis instead relies on the QQ4 2024 filing metrics to infer strategic tone and catalysts. In a typical biotech call, investors would watch for:
- Pipeline progress and lead-program milestones (PRP) and any preclinical data updates.
- Financing strategy and runway length given the continued cash burn and negative equity.
- Potential strategic partnerships or licensing discussions to monetize the pipeline.
- Updates on collaborations (e.g., POP1 program with University of Jaen) and timelines for readouts or IND opportunities.
- Any cost-reduction initiatives or operational optimization signals.
Since the transcript is not available, the above themes are anticipated discussion points rather than quotes or explicit management guidance from the QQ4 2024 call.
N/A
— N/A
N/A
— N/A
Forward Guidance
No formal forward guidance is presented in the provided QQ4 2024 data. Given the company’s preclinical stage and lack of revenue, future outcomes will hinge on:
- Progress or data readouts for the PRP program and other preclinical assets.
- Ability to secure partnering/licensing deals or milestone-based financing to extend the cash runway.
- Regulatory milestones or IND timing that could unlock development funding or collaboration opportunities.
- Overall biotech capital markets conditions and the company’s ability to access capital at acceptable terms.
Assessment: The lack of revenue and negative equity imply a high-risk profile. Achievability of near-term targets depends on securing a meaningful partnership or additional financing before liquidity deteriorates further. Investors should monitor any upcoming press releases, clinical readouts, or strategic updates that could alter the funding trajectory or unlock value from the pipeline.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
PPCB Focus
0.00%
0.00%
9.49%
-43,405.00%
RAIN
0.00%
0.00%
22.10%
-3.05%
OCEA
0.00%
0.00%
-6.62%
58.80%
HEPA
88.80%
-94.86%
-1.52%
-33.40%
IOVA
-28.21%
-251.57%
-19.90%
-4.47%
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
Given the QQ4 2024 results, Propanc Biopharma represents a high-risk, high-uncertainty investment in a microcap biotech with an underylingly fragile financial position and no revenue to date. The key drivers of any potential upside are advancement or favorable readouts of the PRP program, strategic licensing or partnerships, and the ability to secure additional financing at acceptable terms to extend runway. Absent a credible near-term catalyst or an outsized licensing deal, the investment thesis remains highly speculative. Investors should demand clarity on runway length, upcoming catalysts, and any management plan to achieve sustainable financing, while closely monitoring liquidity metrics, debt levels, and any strategic updates directly from the company.
Key Investment Factors
Growth Potential
High-risk, high-reward biotechnology opportunity. Propanc is in the preclinical stage with PRP as a lead program. Potential growth exists if data readouts are favorable or if a licensing/partnership deal accelerates value creation and extends runway. Catalysts would include positive preclinical data, strategic licensing, or collaboration milestones.
Profitability Risk
Major downside risk given: (1) no reported revenue; (2) negative equity and material liabilities; (3) extreme liquidity constraints (current ratio ~0.007, cash ratio ~0.006); (4) dependence on external financing (debt and equity dilutive events likely); (5) clinical/regulatory, scientific, and competitive risks inherent in oncology biotech; (6) potential for further capital raises to fund operations, which could dilute existing shareholders.
Financial Position
Extremely fragile balance sheet with minimal assets relative to liabilities. Total assets $72k vs. total liabilities $3.85M; negative stockholders’ equity of approximately $3.78M. Net debt approximately $927k. Cash burn persists (CFO -$259.97k for QQ4 2024) with financing activities providing only a partial cushion (+$250.97k). Liquidity and capital structure constraints imply a narrow runway and heightened sensitivity to market conditions and fundraising terms.
SWOT Analysis
Strengths
Lead program PRP in preclinical development with potential disease-targeting mechanisms in pancreatic, ovarian, and colorectal cancers.
Strategic collaboration with University of Jaen on POP1 joint drug discovery program, signaling ongoing R&D pipeline activity.
Weaknesses
No revenue reported for QQ4 2024 and ongoing operating losses.
Severe liquidity constraints with current and cash ratios well below peers.
Negative equity and high liabilities raise going-concern concerns.
Heavy dependence on external financing to sustain operations.
Opportunities
Potential licensing/partnership deals to monetize the pipeline and extend runway.
Procurement of data readouts or collaborations that could attract strategic investors.
Regulatory milestones or collaborations that may de-risk and validate the platform.
Threats
Dilutive capital raises could further erode existing shareholders’ value.
Competitive biotech landscape with longer-established oncology players advancing in similar modalities.
Regulatory, scientific, or data-readout risks could delay or derail value realization.
Macro biotech funding environment volatility impacting ability to raise capital.